TY - JOUR
T1 - Combining CRISPRi and metabolomics for functional annotation of compound libraries
AU - Anglada-Girotto, Miquel
AU - Handschin, Gabriel
AU - Ortmayr, Karin
AU - Campos, Adrian I.
AU - Gillet, Ludovic
AU - Manfredi, Pablo
AU - Mulholland, Claire V.
AU - Berney, Michael
AU - Jenal, Urs
AU - Picotti, Paola
AU - Zampieri, Mattia
N1 - Funding Information:
We thank U. Sauer for supporting this work and providing laboratory facilities, N. de Souza for helpful feedback and discussions, the Gross and K.C. Huang groups at UCSF and Stanford for discussions and sharing the E. coli CRISPRi library ahead of publication and T.J. de Wet and D.F. Warner at the University of Cape Town for sharing the CRISPRi mutants in M. smegmatis. This work was supported by an NCCR AntiResist project funding to M.Z., U.J. and P.P. (1-006425); P.P. and L.G. were additionally funded by the European Research Council (grant agreement number 866004), EPIC-XS, project number 823839, funded by the Horizon 2020 programme of the European Union and through a Personalized Health and Related Technologies grant (PHRT-506). C.M. and M.B. were supported by NIH grant AI133191.
Funding Information:
We thank U. Sauer for supporting this work and providing laboratory facilities, N. de Souza for helpful feedback and discussions, the Gross and K.C. Huang groups at UCSF and Stanford for discussions and sharing the E. coli CRISPRi library ahead of publication and T.J. de Wet and D.F. Warner at the University of Cape Town for sharing the CRISPRi mutants in M. smegmatis. This work was supported by an NCCR AntiResist project funding to M.Z., U.J. and P.P. (180541); P.P. and L.G. were additionally funded by the European Research Council (grant agreement number 866004), EPIC-XS, project number 823839, funded by the Horizon 2020 programme of the European Union and through a Personalized Health and Related Technologies grant (PHRT-506). C.M. and M.B. were supported by NIH grant AI133191.
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Nature America, Inc.
PY - 2022/5
Y1 - 2022/5
N2 - Molecular profiling of small molecules offers invaluable insights into the function of compounds and allows for hypothesis generation about small-molecule direct targets and secondary effects. However, current profiling methods are limited in either the number of measurable parameters or throughput. Here we developed a multiplexed, unbiased framework that, by linking genetic to drug-induced changes in nearly a thousand metabolites, allows for high-throughput functional annotation of compound libraries in Escherichia coli. First, we generated a reference map of metabolic changes from CRISPR interference (CRISPRi) with 352 genes in all major essential biological processes. Next, on the basis of the comparison of genetic changes with 1,342 drug-induced metabolic changes, we made de novo predictions of compound functionality and revealed antibacterials with unconventional modes of action (MoAs). We show that our framework, combining dynamic gene silencing with metabolomics, can be adapted as a general strategy for comprehensive high-throughput analysis of compound functionality from bacteria to human cell lines. [Figure not available: see fulltext.]
AB - Molecular profiling of small molecules offers invaluable insights into the function of compounds and allows for hypothesis generation about small-molecule direct targets and secondary effects. However, current profiling methods are limited in either the number of measurable parameters or throughput. Here we developed a multiplexed, unbiased framework that, by linking genetic to drug-induced changes in nearly a thousand metabolites, allows for high-throughput functional annotation of compound libraries in Escherichia coli. First, we generated a reference map of metabolic changes from CRISPR interference (CRISPRi) with 352 genes in all major essential biological processes. Next, on the basis of the comparison of genetic changes with 1,342 drug-induced metabolic changes, we made de novo predictions of compound functionality and revealed antibacterials with unconventional modes of action (MoAs). We show that our framework, combining dynamic gene silencing with metabolomics, can be adapted as a general strategy for comprehensive high-throughput analysis of compound functionality from bacteria to human cell lines. [Figure not available: see fulltext.]
UR - http://www.scopus.com/inward/record.url?scp=85125071653&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125071653&partnerID=8YFLogxK
U2 - 10.1038/s41589-022-00970-3
DO - 10.1038/s41589-022-00970-3
M3 - Article
C2 - 35194207
AN - SCOPUS:85125071653
SN - 1552-4450
VL - 18
SP - 482
EP - 491
JO - Nature Chemical Biology
JF - Nature Chemical Biology
IS - 5
ER -